Diffuse large B-cell lymphoma with low ¹⁸F-fluorodeoxyglucose avidity features silent B-cell receptor signaling

References

• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242.
   PubMed Web of Science ®Google Scholar
• Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene. 2007;26(25):3603–3613.
   PubMed Web of Science ®Google Scholar
• Sud R, Friedberg JW. Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab. Haematologica. 2008;93(12):1776–1780.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Blum KA, Kahl BS, et al. Beyond RCHOP: a blueprint for diffuse large B cell lymphoma research. J Natl Cancer Inst. 2016;108(12):djw257.
   PubMedGoogle Scholar
• Cornall RJ, Cheng AM, Pawson T, et al. Role of Syk in B-cell development and antigen-receptor signaling. Proc Natl Acad Sci USA. 2000;97(4):1713–1718.
   PubMed Web of Science ®Google Scholar
• Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008;111(4):2230–2237.
   PubMed Web of Science ®Google Scholar
• Chen L, Monti S, Juszczynski P, et al. SYK inhibition modulates distinct PI3K/AKT-dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell. 2013;23(6):826–838.
   PubMed Web of Science ®Google Scholar
• Doughty CA, Bleiman BF, Wagner DJ, et al. Antigen receptor-mediated changes in glucose metabolism in B lymphocytes: role of phosphatidylinositol 3-kinase signaling in the glycolytic control of growth. Blood. 2006;107(11):4458–4465.
   PubMed Web of Science ®Google Scholar
• Dal Porto JM, Gauld SB, Merrell KT, et al. B cell antigen receptor signaling 101. Mol Immunol. 2004;41(6–7):599–613.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922–926.
   PubMed Web of Science ®Google Scholar
• Ma J, Xing W, Coffey G, et al. Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma. Oncotarget. 2015;6(41):43881–43896.
   PubMedGoogle Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–516.
   PubMed Web of Science ®Google Scholar
• Younes A, Thieblemont C, Morschhauser F, et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol. 2014;15(9):1019–1026.
   PubMed Web of Science ®Google Scholar
• Meignan M, Itti E, Gallamini A, et al. FDG PET/CT imaging as a biomarker in lymphoma. Eur J Nucl Med Mol Imaging. 2015;42(4):623–633.
   PubMed Web of Science ®Google Scholar
• Bensinger SJ, Christofk HR. New aspects of the Warburg effect in cancer cell biology. Semin Cell Dev Biol. 2012;23(4):352–361.
   PubMed Web of Science ®Google Scholar
• Upadhyay M, Samal J, Kandpal M, et al. The Warburg effect: insights from the past decade. Pharmacol Ther. 2013;137(3):318–330.
   PubMed Web of Science ®Google Scholar
• Koppenol WH, Bounds PL, Dang CV. Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11(5):325–337.
   PubMed Web of Science ®Google Scholar
• Vander HM, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–1033.
   PubMed Web of Science ®Google Scholar
• Valls L, Badve C, Avril S, et al. FDG-PET imaging in hematological malignancies. Blood Rev. 2016;30(4):317–331.
   PubMed Web of Science ®Google Scholar
• Weiler-Sagie M, Bushelev O, Epelbaum R, et al. F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51(1):25–30.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Liu C, Zhang Y, Zhang Y, et al. Diagnostic value of 18F-FDG PET/CT for cutaneous extranodal natural killer/T-cell lymphoma, nasal type. Nucl Med Commun. 2016;37(5):446–452.
   PubMed Web of Science ®Google Scholar
• Yang Z, Cheng J, Pan L, et al. Is whole-body fluorine-18 fluorodeoxyglucose PET/CT plus additional pelvic images (oral hydration-voiding-refilling) useful for detecting recurrent bladder cancer? Ann Nucl Med. 2012;26(7):571–577.
   PubMed Web of Science ®Google Scholar
• Hirose Y, Suefuji H, Kaida H, et al. Relationship between 2-deoxy-2-[(18)F]-fluoro-d-glucose uptake and clinicopathological factors in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2014;55(3):520–525.
   PubMed Web of Science ®Google Scholar
• Schoder H, Noy A, Gonen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:4643–4651.
   PubMed Web of Science ®Google Scholar
• Bogusz AM, Baxter RH, Currie T, et al. Quantitative immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma. Clin Cancer Res. 2012;18(22):6122–6135.
   PubMed Web of Science ®Google Scholar
• Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88–92.
   PubMed Web of Science ®Google Scholar
• Sommermann TG, O’Neill K, Plas DR, et al. IKKbeta and NF-kappaB transcription govern lymphoma cell survival through AKT-induced plasma membrane trafficking of GLUT1. Cancer Res. 2011;71(23):7291–7300.
   PubMed Web of Science ®Google Scholar
• Ju HQ, Zhan G, Huang A, et al. ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition. Leukemia. 2017;31(10):2143–2150.
   PubMed Web of Science ®Google Scholar
• Wang WG, Cui WL, Wang L, et al. Loss of B-cell receptor expression defines a subset of diffuse large B-cell lymphoma characterized by silent BCR/PI3K/AKT signaling and a germinal center phenotype displaying low-risk clinicopathologic features. Am J Surg Pathol. 2015;39(7):902–911.
   PubMed Web of Science ®Google Scholar
• Wang WG, Jiang XN, Liu ZB, et al. MYC protein-positive diffuse large B-cell lymphoma features an activated B-cell receptor signal pathway. Am J Surg Pathol. 2017;41(4):541–549.
   PubMed Web of Science ®Google Scholar
• Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105(5):1851–1861.
   PubMed Web of Science ®Google Scholar
• Caro P, Kishan AU, Norberg E, et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell. 2012;22(4):547–560.
   PubMed Web of Science ®Google Scholar